Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-01-02 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物关于募集资金投资项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Hangzhou Anxu Biotech Co., Ltd. regarding the delay of investment projects funded by raised capital. It details the original and postponed completion dates of various projects, reasons for the delay, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but focuses on the status and management of capital investment projects. It is a regulatory announcement about capital investment project delays, which fits the category of Capital/Financing Update (CAP). The document length is about 4704 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the classification is CAP with high confidence.
2024-01-02 Chinese
安旭生物关于调整公司第二届审计委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the adjustment of members of the company's second audit committee. It details changes in the board committee membership, specifically the audit committee, including names and roles before and after the change. There is no financial data, no report attached or referenced as being published, and no mention of voting results or dividends. The content is about board/committee membership changes, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on management/board committee changes, confirming the classification.
2024-01-02 Chinese
安旭生物关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting of shareholders for Hangzhou Anxu Biotechnology Co., Ltd. It includes information about the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. There is no financial data, earnings information, or report content. It is clearly an announcement of a shareholders meeting, not the meeting materials or results. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document is not a report publication announcement since it contains substantive meeting details rather than just a brief notice of report availability.
2024-01-02 Chinese
安旭生物董事会薪酬与考核委员会工作细则（2024年1月修订）
Governance Information Classification · 95% confidence The document is titled "董事会薪酬与考核委员会工作细则" which translates to "Board of Directors Remuneration and Assessment Committee Working Rules". It details the structure, responsibilities, and procedures of the board committee responsible for remuneration and assessment of directors and senior management. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, no earnings release, and no investor presentation. The document is a governance-related internal rules document about board committee operations and remuneration policies. Therefore, it fits the category of Governance Information (CGR). The document length is 2974 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Hence, the classification is CGR with high confidence.
2024-01-02 Chinese
安旭生物董事会提名委员会工作细则（2024年1月修订）
Governance Information Classification · 100% confidence The document is titled '董事会提名委员会工作细则' which translates to 'Board Nomination Committee Working Rules'. It details the structure, responsibilities, and procedures of the board nomination committee, including the nomination and appointment of directors and senior management. There is no financial data, earnings information, or report publication mentioned. The content focuses on governance practices and internal rules related to board and management nominations. Therefore, it fits the category of Governance Information (CGR). The document length is 2726 characters, which is consistent with a detailed governance policy document rather than a brief announcement or report publication.
2024-01-02 Chinese
杭州安旭生物科技股份有限公司关于召开2023年第三季度业绩说明会的公告
Investor Presentation Classification · 75% confidence The document is an announcement about the scheduling of a 2023 third quarter earnings explanation meeting (业绩说明会) by Hangzhou Anxu Biotechnology Co., Ltd. It specifies the date, time, location, and format of the meeting, and invites investors to participate and submit questions. It references that the company has already released the 2023 Q3 report on October 31, 2023, but this document itself does not contain financial data or the report itself. The document is short (1477 characters) and serves as a notice for an upcoming earnings call or presentation rather than the actual report or transcript. Therefore, it is best classified as an Investor Presentation announcement or related to earnings explanation meetings. Given the options, the closest match is Investor Presentation (IP), as it is a detailed presentation for investors focusing on financials and strategy, even though this is an announcement of the meeting rather than the presentation itself. However, since it is an announcement of the meeting and not the presentation content, it could also be considered a Regulatory Filing (RNS). But given the detailed nature and focus on the earnings explanation meeting, Investor Presentation (IP) is the best fit with moderate confidence.
2023-11-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.